AbbVie purchases neuroscience developer Cerevel for $8.7B

By STAT News
| December 07, 2023

The deal marks the second billion-dollar acquisition by AbbVie in under a week. The company also acquired Immunogen and its ovarian cancer treatment for $10 billion.

Full story

#1

Physicians are in short supply. They are costly. Is the APP the answer to the CMO's workforce and budget challenges? ...

Amid the hype and promise, a growing tension is becoming clear: the reality of what AI can deliver versus what it can't. ...